We can provide strategies (like adjusting meal timing or hydration) or even temporarily modify your dose to make you more comfortable
Available from: 11.Girish P., Abdelmalak M.D., Wade A
The current Triple agonists in Phase 2 and Phase 3 development have recorded even better results with early trials with some of the candidates showing weight loss up to 27% in clinical trials and this was comparable to the effects of bariatric surgery without surgery
Tolerability and additional side effects may vary by patient and formulation
The 2015 regional fact sheet of IDF estimates the prevalence to be 10.7%, 8.5%, and 3.2% in the Middle East and North Africa (MENA), South East Asia (SEA), and African regions, respectively.[1] This increasing burden of the disease may contribute to increased rate of complications, reduction of quality of life, and premature mortality
Semaglutide (marketed under brand names like Wegovy and Ozempic) and Tirzepatide (Mounjaro and Zepbound) are GLP-1 receptor agonists that help regulate appetite, insulin, and metabolism